CAR-T Followed by Bispecific Antibodies
Phase 2
42
about 5.7 years
18+
2 sites in NE, PA
What this study is about
Researchers are testing the safety and effectiveness of mosunetuzumab or a combination of obinutuzumab and glofitamab after CAR T-cell treatment in patients with DLBCL. The trial will last for approximately 2 years.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take glofitamab
- 2.Take mosunetuzumab
- 3.Take obinutuzumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
glofitamab, mosunetuzumab, obinutuzumab
injection, intravenous
Primary: Assessment of the percentage of subjects who experience hematologic dose limiting toxicity associated with early administration of Mosunetuzumab and glofitimab following SOC CAR-T Cell therapy in patients who stop therapy after 2 cycles., Assessment of the percentage of subjects who experience non-hematologic dose limiting toxicity associated with early administration of glofitimab following SOC CAR-T Cell therapy., Assessment of the percentage of subjects who experienced non-hematologic dose limiting toxicity associated with early administration of Mosunetuzumab following SOC CAR-T Cell therapy.
Oncology